SUMMARY Patients with acute leukaemia have normal or near normal numbers of haemopoietic stem cells in their marrow at diagnosis. Remission is achieved when the administration of cytotoxic drugs eradicates the bulk of the leukaemic population while sparing normal haemopoiesis. The mechanism by which chemotherapy seems to act in this selective manner is essentially unknown. Nevertheless, remission rates of 80-95% can be achieved in children and in 50-80% of adults with acute leukaemia. Attempts to cure patients in remission may entail either "continuing curative chemotherapy" or "supralethal" doses of chemoradiotherapy followed by autologous or allogeneic bone marrow transplantation. The relative merits of these different methods remain highly controversial but chemotherapy is usually the preferred method of continuing treatment for children with acute lymphoblastic leukaemia in first remission; and allogeneic transplantation is recommended for younger adults with acute myeloid leukaemia who have suitable HLA-identical sibling donors. The role of autografting is still experimental. Patients with chronic myeloid leukaemia can achieve long term remission and probably cure following allogeneic bone marrow transplantation but the resultant risks of mortality are still appreciable. Chronic lymphocytic leukaemia currently remains incurable.
In the space of a mere 20 years the prospects for worthwhile treatment and cure for many patients with leukaemia have improved very considerably. The diagnosis of acute leukaemia in the 1950s and early 1960s was associated with justifiable pessimism; remissions were obtained with some regularity in children with acute lymphoblastic leukaemia (ALL) but rarely in adults with acute myeloid leukaemia (AML). Those remissions that were obtained lasted several months and second remissions were rare.
The results of treating leukaemia in 1987 prove that progress has been made. Perhaps 95% of children with "standard" risk ALL will achieve complete remission and 70-80% of these can expect long term disease free survival. For younger adults with AML the remission rate is nearly 80% and 25% of these patients who receive further chemotherapy in remission may be cured. Allogeneic bone marrow transplantation was introduced in the 1970s and has become standard treatment for selected patients with acute leukaemia. The "actuarial cure" rates are unquestionably high, but disease free survival curves invariably reflect the high risk of death in remission from complications associated with transplantation, notably graft versus host disease and pneumonitis. Other patients with acute leukaemia have-been treated by autografting in first or second remission. It is still too early to evaluate the results of this approach but preliminary results are sufficiently encouraging to justify more widespread use of this technique.
Though the newcomer to the field may be familiar with the various advances outlined above, he or she may be less familiar with the details of the academic polemics in which some of the leading therapists have become involved. There have always been and continue to be caring clinicians who oppose the introduction of new schedules of cytotoxic drugs that seem to be very aggressive, or the application of new modalities, such as bone marrow transplantation, for diseases that at least in the short term seem to be innocuous. These conservative opinions are important, for they restrain the overenthusiastic chemotherapist by reminding him that ultimately many of his efforts must inexorably fail. This said, it is only by realising that today's results, better though they are than those of yesteryear, are still inadequate, and it is only by constantly planning modifications in treatment schedules that we can hope to progress.
Principles of treatment THE P-HYSIOLOGICAL BASIS OF REMISSION
The typical patient with acute leukaemia has a bone 985 986 marrow densely packed with blast cells and large numbers of blast cells in the circulation. If treatment is effective the same patient can have a bone marrow that appears entirely normal even to the experienced observer within three to four weeks. Even the most technologically advanced methods may be unable to detect the small numbers of residual leukaemic cells that are presumably present in the marrow. Though the term "complete remission in acute leukaemia" is formally defined as "less than 5% of blast cells in a marrow of normal cellularity in conjunction with a normal blood count," for operational purposes 987 one or more years of further chemotherapy-so called late intensification. All these techniques may be grouped under the general heading of continuing curative chemotherapy. 13 The idea that increasing the dose of cytotoxic drugs administered in a single course might be the best method of curing acute leukaemia is inherent in the use of bone marrow transplantation, be it with autologous or allogeneic stem cells, to rescue the patient from the prolonged and perhaps irreversible marrow failure that would otherwise follow. The use of transplant techniques also permits the administration of relatively high doses of radiotherapy to the whole body. The maximum possible dose, however, is limited by the susceptibility of the lung to damage by doses of radiation above 10 Gy, administered as a single dose or above 14 to 15 Gy administered in fractions over three to seven days.
Thus for the patient with acute leukaemia who achieves complete remission, there are three choices for continuing curative treatment: chemotherapy, autografting, or allografting. No one of these approaches is obviously optimal, and the best option for an individual patient will depend, inter alia, on age, the type of leukaemia and associated prognostic features, the availability of an HLA-matched donor; and, not least, the expertise and preferred practice at the centre of treatment.
Chemotherapy for remission induction
In the 1960s patients with AML used to be treated with corticosteroids, 6-mercaptopurine, or not at all. Remissions were obtained in 10-20% of patients but these were usually short lived, and for most patients the value of any but supportive treatment was not clear cut. The introduction of additional drugs with major antileukaemic activity, notably cytosine arabinoside and the anthracyclines, resulted in remission rates in the 1970s that ranged between 40 and 60% (table 1). In the past few years specialist centres in many countries have gained experience with the use of cytosine arabinoside administered by intravenous infusion for seven to 10 days in conjuction with three doses of an anthracycline (usually daunorubicin but sometimes doxorubicin). Some centres prefer to give Goldman rather lower, perhaps 80-90%, in children with poor prognosis features and in adults. This means that 10-20% of selected patients with ALL never achieve complete remission. In these cases failure is usually due to early death or relative resistance of the leukaemic population, and death in prolonged aplasia is rare. It is difficult, however, to see how a standardised remission induction could be intensified without jeopardising survival in the majority of patients for whom the more intensive treatment would be excessive. Future studies will probably attempt to define more precisely the small category of patients for whom more intensive remission induction is required.
In some senses the outstanding problems of remission induction are best exemplified by CML. At diagnosis the finding of the Ph chromosome in every or almost every marrow metaphase suggests that most haemopoiesis is leukaemic, but occasional patients can be restored to normal (Ph negative) haemopoiesis by appropriate chemotherapy. This suggests that all patients at diagnosis have substantial numbers of normal stem cells in their marrow which have been induced to a state of inactivity (prolonged Go) by the leukaemic proliferation, a situation analogous to that thought to exist in the acute leukaemias. The experimental results of the Vancouver group, which showed the presence of appreciable numbers of normal progenitor cells when the marrow from newly diagnosed patients was cultured in vitro, substantiate this idea."7 18 The analogy with acute leukaemia breaks down, however, because none of the available cytotoxic drugs is sufficiently selective in its ability to damage leukaemic cells while sparing normal stem cells. It is likely, however, that methods will be developed for induction of complete remission in CML as is now the case in acute leukaemia.
Continuing curative chemotherapy CONSOLIDATION AND EARLY INTENSIFICATION IN AML
A considerable number of studies have now been reported in which patients who achieve complete remission after induction treatment have received further courses either with the same drugs as were used for induction or with other combinations. The present regimen used at this hospital incorporates both approaches.15 Thus patients in remission after one course receive a second course of cytosine arabinoside, 6 -thioguanine (both for eight days), together with daunorubicin (on three alternate days). They subsequently receive up to four additional courses of cytotoxic drugs, together comprising in various schedules the use of amsacrine, 5-azacytidine, etoposide, cytosine arabinoside in high doses, 
THE NEED FOR PURGING
A major theoretical objection to the use of autologous bone marrow transplantation in the attempt to cure acute leukaemia relates to the possibility that leukaemic stem cells might be present in the bone marrow harvested in remission and that these cells might reinduce leukaemia after its otherwise successful eradication. This, however, is far from certain; the number of leukaemic stem cells (as distinct from recognisable blast cells) capable of reinducing acute leukaemia, which are present in the bone marrow in remission, could be very small, and high numbers might not necessarily be collected in a standard bone marrow harvest. Moreover, cure of leukaemia might not require total eradication of such stem cells (as mentioned above); a major reduction in their number, which could be achieved by an autograft procedure, might permit the reactivation of immune or other mechanisms that could indefinitely prevent their further proliferation. It is difficult to design studies to 
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The principal results of these clinical studies show that a chosen method for in vitro manipulation spares normal stem cells and permits reconstitution of autologous haemopoiesis. If relapse occurs it is difficult to discern whether it originated from leukaemic cells in the body or leukaemic cells in the harvested marrow. The distinction could perhaps be based on the finding of cytogenetic changes related to radiation in the cells at relapse after autografting.30 Eventually it will be essential to perform clinical studies in which the relapse rates in patients autografted with purged and unpurged marrow cells can be compared.
There are other possible approaches designed to cure patients that obviate the need for purging harvested marrow. Clinicians at the University College Hospital in London have reasoned that the chance of cure could be greatly increased if patients were subjected to a second autograft using bone marrow stem cells collected after the first procedure.31 This approach might act as a form of "in vivo purging" by which short term regeneration of marrow after the first procedure would favour the growth of normal haemopoietic cells and the number of leukaemic cells harvested on the second occasion would thus be minimal. Alternatively, blood stem cells present in the circulation could be used for the autograft procedure at appropriate times after remission was achieved.32 3 It seems reasonable to assume, though no proof exists, that leukaemic stem cells might circulate less than their normal counterparts. Several recent clinical studies document the ability of stem cells derived from blood to reconstitute haemopoiesis after supralethal chemoradiotherapy.34 It is too early to say whether their use will offer benefits comparable with the use of unpurged autologous marrow cells. A third method of purging entails the use of autologous marrow that has been maintained for some days in liquid culture. The Manchester group published preliminary data indicating that marrow cells obtained from patients with AML in relapse can restore normal haemopoiesis, when transfused after administration of cyclophosphamide and total body irradiation. 35 Presumably most of the leukaemic cells died during the in vitro incubation period.
RESULTS OF AUTOGRAFTING FOR ACUTE LEUKAEMIA
The results of treating patients with acute leukaemia in remission are still preliminary (table 4). In general no specialist centre has experience extending over a period greater than three years, and the survival plateaux are still therefore "unstable". Moreover, some of the results of the single centre series are open to the criticism that a proportion of patients autografted in remission had already been in remission for some months or even years before the autograft procedure Goldman was undertaken. Such selection will, of course, bias results in favour of autografting. There is undoubtedly a need for prospective multicentre studies in which the criteria for patient eligibility, the choice of antileukaemic treatment, and the assessment of results are all standardised. Such studies are now in progress.
Allografting
The techniques of bone marrow transplantation were developed in the 1960s and 1970s using animal model systems. The discovery of the HLA system in man, broadly analogous to the H2 histocompatability system in mice, underpinned the first successful human transplants. It is now clear that transplantation using HLA-identical siblings of a patient are often successful, although graft versus host disease still occurs with an incidence of 40-70% and can be lethal in some cases. The other major cause of morbidity and mortality after transplantation is interstitial pneumonitis, sometimes associated with pulmonary infection with cytomegalovirus, but at other times without obvious cause. In the latter cases the pneumonitis is termed idiopathic, although the pulmonary reaction is probably a response to the combined toxic effects of alkylating agents and irradiation. The first systematic efforts to treat acute leukaemia by allogeneic bone marrow transplantation were carried out in the 1970s.36 The patients were in relapse and their disease was, to varying extents, resistant to available antileukaemic drugs. Nevertheless, the administration of high doses of cyclophosphamide followed by total body irradiation and transfusion of allogeneic bone marrow cells resulted in long term survival for about 12% of patients in the series reported from Seattle. These relatively encouraging results led to speculation that an allograft performed in remission might be expected to cure a higher proportion of patients. Since 1976 more than 5000
Prospects for cure in leukaemia For patients with AML in first remission, the probability of disease free survival at four years is 40-50%.37 Though some relapses have occurred later than four years, these seem to be rare and most of the patients alive at four years can expect to be cured. For patients transplanted in second or subsequent 100 c80 4'1 .> E (3 401 0 991 remission, the chance of cure is about 30%. Some preliminary evidence suggests that patients transplanted in early relapse after a period of remission may fare almost as well as those transplanted in first remission.39 If this were confirmed it would provide a partial solution for the difficult question of whether to transplant the younger patient with AML in remission who has an HLA-identical sibling to act as donor. It would mean that the patient could be treated initially with the best available chemotherapy schedule as consolidation. He might have a 20-25% chance of being cured. If, however, he were to relapse, he could be transplanted with perhaps a 40% chance of cure. This would mean that the overall probability of cure for a patient newly in remission would be about 25% + (40 x 75%) = 55%. The main objections to this approach might be the difficulty in recognising the patient in early relapse and the inconvenience (and in some cases impossibility) of submitting a patient to what amounts in practice to an "emergency transplant". There is no evidence that any form of conventional chemotherapy cures, or indeed, considerably prolongs life for patients with chronic myeloid leukaemia. In the 1970s the Seattle group reported the results of attempts to treat CML by allogeneic bone marrow transplant. These were largely unsuccessful. More recently the group in Seattle and others pioneered attempts to treat patients with CML by bone marrow transplantation in chronic phase.4243 After about eight years of experience with this approach one can say with virtual certainty that though the mortality associated with transplantation is still substantial (fig 2) , most patients who survive beyond three years can be regarded as cured. The probability of relapse is about 10% (table 5) and the probability of disease free survival at four years 45-55%. 4 For patients transplanted in the accelerated or blastic phases of CML, the corresponding figures are about 40 and 20%, respectively.
On the basis of these figures, it can be confidently said that any patient with CML under the age of 45 or 50 who has an HLA-identical sibling should be offered the chance of treatment by bone marrow transplantation. The transplant should undoubtedly be performed while the patient remains in the chronic phase of CML, but the optimal timing of the procedure within the chronic phase can not yet be specified. Data from Seattle suggest that the duration of chronic phase is directly related to the probability of survival, a finding that would favour transplant as soon as is convenient after diagnosis.1I In the analysis performed by the International Bone Marrow Transplant Registry, however, no such correlation was identified (Goldman JM, Gale RP, Bortin MM, et al, unpublished observations). One approach is to use a patient's prognostic factors at diagnosis to assess the probability of transformation within a given time Conversely, the probability of relapse seems to be higher in patients with acute leukaemia transplanted with marrow from identical twins, a situation in which the donor T lymphocytes presumably have an immunological potential indistinguishable from that of the patient. Finally, it has been recognised very recently that the probability of relapse in patients transplanted for CML, and probably also in patients with acute leukaemia, is significantly higher if they receive marrow cells depleted of T cells in vitro for prevention of graft versus host disease in man (Goldman JM, Gale RP, Bortin MM, et al, unpublished observations). 47 These separate lines of evidence all suggest that the cure of leukaemia results both from the effects of the chemoradiotherapy and from a GVL effect mediated by T lymphocytes originating from the donor. An important challenge for the future will be to ascertain whether GVL in man is mediated by the same population of lymphocytes that are responsible for the generation of graft versus host disease.
Prospects for the future There has been a steady increase in the incidence of complete remission for younger patients with acute leukaemia. Although several newer cytotoxic drugs have become available in the past few years, it seems unlikely that their use, instead of or in addition to existing schedules, will have any important impact on the incidence of complete remission. Furthermore, the problem for the older patient, who tolerates chemotherapy less well and who less predictably recovers normal haemopoiesis, will not be solved by escalating the intensity of chemotherapy. Of considerable interest, however, is the recent report from Manchester of the use of autologous bone marrow cells incubated in short term liquid culture to rescue patients after high dose chemoradiotherapy for AML in relapse. This culture system seems to permit selective survival of residual normal haemopoietic stem cells at the expense of leukaemic cells. If these fascinating results can be replicated in a larger number of patients the approach might be applied more widely to induce initial remission in patients whose disease is deemed unlikely to respond to cytotoxic drugs administered in standard doses.
For continuing curative chemotherapy the repeated use of cytotoxic drug combinations similar to those that induced complete remission does not seem to increase the probability of cure to any great extent. It seems more likely that schedules incorporating some of the newer drugs, such as amsacrine, mitoxantrone, or bisantrene, or existing drugs used in new ways, such as etoposide or high dose cytosine arabinoside, will contribute to cure. Conversely, it seems unlikely that minor chemical modifications of existing drugs, of which the various anthracycline analogues are examples, will make any worthwhile impact on the cure rate.
There is undoubtedly scope for designing new schedules of chemotherapy to precede autografting for acute leukaemia. Cyclophosphamide is not particularly active in AML and etoposide or cytosine arabinoside could prove more effective in eradicating leukaemic cells. The questions of whether or how to give total body irradiation before autografting are unresolved. Likewise the need for purging is not yet established; if it is, then many possible techniques are available. Indeed, the number of variables in the autograft procedure permit almost limitless combinations, but large multicentre clinical studies must nevertheless be designed to address and hopefully answer some of these questions.
The actuarial cure rates following allogeneic bone marrow transplantation for acute leukaemia and CML using unmanipulated donor marrow cells are undoubtedly higher than can be achieved by any other approach. Though graft versus host disease can largely be prevented by T cell depletion, preliminary evidence suggests that the relapse rate may be increased, especially in CML, and that survival for patients with CML and possibly for those with acute leukaemia is not correspondingly increased. Interstitial pneumonitis remains a major problem. Thus there is no immediate prospect of any worthwhile reduction in the incidence of mortality associated with transplantation nor consequently of any increase in the probability of disease free survival either in acute leukaemia or CML. It is more likely that progress in this area over the next five years will relate to more successful use of matched unrelated donors or one antigen mismatched family member donors. Furthermore, it may prove possible to transplant patients relatively safely in the fifth and even sixth decade of life. These developments will mean that transplantation may be more widely available but it will remain an extremely hazardous procedure for some time to come.
